Antifungal Classes

Fungal infections have afflicted humans for millennia, yet the pharmacological arsenal to treat them is remarkably young compared to antibacterial agents. For much of the twentieth century, clinicians had very few options for treating systemic mycoses, and mortality rates for invasive candidiasis and aspergillosis remained devastatingly high. The development of antifungal pharmacotherapy was hampered by a fundamental challenge: because fungi are eukaryotes—like human cells—identifying drug targets that selectively harm the pathogen without injuring the host proved far more difficult than targeting prokaryotic bacteria. This selectivity problem drove decades of research into the unique biochemical features of fungal cells, particularly their reliance on ergosterol rather than cholesterol in their cell membranes, and the presence of a rigid β-glucan cell wall absent from mammalian cells.

The historical trajectory of antifungal development reveals a persistent question that continues to shape modern pharmacology: how can we exploit the subtle biochemical differences between fungal and human cells to develop agents that are both efficacious and well-tolerated? Understanding the major antifungal drug classes—their mechanisms, spectra of activity, pharmacokinetics, and toxicities—is essential for any healthcare professional who manages patients at risk for invasive fungal disease.

All antifungal agents exploit one of a limited number of biological differences between fungal and human cells. A firm grasp of these differences provides the conceptual framework for understanding every antifungal drug class. Fungi, as eukaryotes, share much of their core cellular machinery with humans—ribosomes, mitochondria, and a nucleus—but they diverge in several critical ways. The fungal cell membrane contains ergosterol rather than cholesterol as its principal sterol, and this difference is the basis for both the polyenes and the azoles. Additionally, the fungal cell is surrounded by a rigid cell wall composed largely of chitin and glucan polymers—a structure entirely absent in mammalian cells and the target of the echinocandins.

The diagram above reveals a critical principle: each antifungal class is defined by the specific fungal structure or pathway it disrupts. Notice how the cell membrane is the most densely targeted structure, reflecting the outsized importance of ergosterol in fungal physiology. The polyenes act at a post-synthetic level by binding ergosterol directly, while the azoles and allylamines act at different enzymatic steps in the ergosterol biosynthetic pathway—squalene epoxidase for allylamines and lanosterol 14α-demethylase (CYP51) for azoles. This distinction is pharmacologically important because inhibiting synthesis (azoles) is typically fungistatic, whereas binding the final product and creating membrane pores (polyenes) is fungicidal. The echinocandins occupy a privileged therapeutic niche because their target, β-1,3-glucan synthase, has no human homolog, which explains their remarkably favorable side-effect profile.

Polyenes: Direct Ergosterol Binding

Amphotericin B and nystatin are the clinically relevant polyene antifungals. Amphotericin B is an amphipathic molecule that inserts its hydrophobic polyene chain into the fungal lipid bilayer and binds directly to ergosterol. This binding aggregates multiple amphotericin molecules into a barrel-like structure that forms transmembrane pores, leading to the leakage of potassium ions (K⁺), magnesium, and other intracellular solutes. The resultant osmotic stress and ionic imbalance trigger cell death, rendering amphotericin B fungicidal. Unfortunately, amphotericin B also has some affinity for cholesterol in mammalian cell membranes—particularly in renal tubular epithelial cells—explaining its dose-limiting nephrotoxicity. Lipid formulations (liposomal amphotericin B, amphotericin B lipid complex) reduce nephrotoxicity by preferentially delivering drug to fungal cells and reticuloendothelial tissues.

Azoles: Inhibition of Ergosterol Biosynthesis

The azoles are subdivided into imidazoles (ketoconazole, clotrimazole, miconazole) and triazoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole). All azoles inhibit lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme that converts lanosterol to ergosterol. Depletion of ergosterol and accumulation of toxic methylated sterol intermediates compromise membrane integrity and the function of membrane-associated enzymes. The azoles are generally fungistatic against yeasts (although voriconazole exhibits fungicidal activity against Aspergillus). Because CYP51 shares homology with human hepatic cytochrome P450 enzymes, azoles are potent CYP450 inhibitors and are associated with significant drug–drug interactions, particularly via CYP3A4, CYP2C9, and CYP2C19.

Echinocandins: Cell Wall Disruption

The echinocandins—caspofungin, micafungin, and anidulafungin—are large lipopeptide molecules that non-competitively inhibit β-1,3-glucan synthase, the enzyme responsible for synthesizing β-1,3-glucan, a critical structural polymer of the fungal cell wall. Without this polysaccharide scaffold, the cell wall loses integrity, and the fungal cell lyses due to unrestrained osmotic pressure. Because mammalian cells lack cell walls entirely, echinocandins exhibit excellent selectivity and have the most favorable toxicity profile of all systemic antifungals. They are fungicidal against Candida species and fungistatic against Aspergillus. Their large molecular size necessitates intravenous administration, and they achieve poor penetration into the CNS, eye, and urinary tract.

Allylamines and Flucytosine

Terbinafine is the principal allylamine in clinical use. It inhibits squalene epoxidase, an enzyme upstream of CYP51 in the ergosterol synthesis pathway. Inhibition leads to depletion of ergosterol and accumulation of squalene, which is directly toxic to the fungal cell. Terbinafine is fungicidal and is most commonly used for dermatophyte infections (tinea, onychomycosis) because it accumulates in keratinized tissues. Flucytosine (5-fluorocytosine, 5-FC) is a fluorinated pyrimidine analog that is taken up by fungal cells via cytosine permease and converted intracellularly to 5-fluorouracil (5-FU) by cytosine deaminase. The 5-FU is then metabolized to metabolites that inhibit thymidylate synthase (blocking DNA synthesis) and get incorporated into fungal RNA, disrupting protein synthesis. Because human cells lack cytosine deaminase, selective toxicity is achievable—though myelosuppression can occur when gut flora convert 5-FC to 5-FU systemically. Flucytosine is used almost exclusively in combination with amphotericin B for cryptococcal meningitis to prevent the rapid emergence of resistance.

The following clinical scenario demonstrates how knowledge of antifungal mechanisms, spectra, pharmacokinetics, and toxicities integrates into therapeutic decision-making.

The antifungal landscape is evolving rapidly in response to increasing rates of invasive fungal infections in immunocompromised populations (transplant recipients, patients with HIV/AIDS, those receiving immunosuppressive therapies) and the emergence of multidrug-resistant organisms such as Candida auris. C. auris is particularly alarming because it can demonstrate resistance to all three major systemic antifungal classes simultaneously, persists in healthcare environments, and is difficult to identify with conventional laboratory methods. Understanding current drug classes prepares students to evaluate novel agents in the pipeline.

As you advance in pharmacology and infectious disease coursework, you will encounter these novel agents and learn to evaluate them through the same mechanistic lens established by the current drug classes. The core question remains unchanged: does the agent target a structure or pathway sufficiently distinct from human biology to achieve a favorable therapeutic index? Each new class or novel target represents another answer to the selectivity problem that has defined antifungal drug development since the isolation of amphotericin B in 1955.